

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **HIGHLY SELECTIVE KAT6 INHIBITOR (SYH2095 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2095 tablets (the “**Product**”), an innovative Class 1 chemical drug co-developed by the Group and Hangzhou Innogate Pharma Co., Ltd., have obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. Previously, the Product also obtained approval from the U.S. Food and Drug Administration (FDA) in April 2026 to conduct clinical trials in the U.S.

The Product is a novel lysine acetyltransferase 6 (“**KAT6**”) inhibitor and belongs to a class of epigenetic anticancer drugs. The Product exerts its anti-tumour effects by inhibiting the acetylation of histone lysine, blocking open chromatin, and thereby regulating the cell cycle, estrogen receptor expression, and cellular senescence pathways. It is intended for the treatment of advanced malignant tumour. Preclinical studies showed that the Product demonstrated potent and selective inhibition of KAT6, significantly suppressed tumour growth, and exhibited favourable pharmacokinetic properties and safety profile.

Currently, no drug with the same target has been approved for marketing domestically or internationally, and the Product has significant clinical development value.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 18 May 2026

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.*